Overview
BPC-157 (Body Protection Compound-157) is a 15-amino-acid sequence first isolated as a fragment of a gastric protein in the early 1990s by the Sikiric laboratory in Zagreb. The intact parent protein has not been shown to exist in vivo; the fragment is a synthetic construct designed around a stable region of the gastric proteome.
Preclinical literature on BPC-157 spans rodent models of tendon transection, ligament injury, gut anastomosis, vascular occlusion and toxic insult. The reported pattern is broadly the same across these models: accelerated functional recovery, increased granulation tissue formation, and modulation of nitric-oxide signalling.
Human evidence remains limited. As of writing there are no completed phase-III trials, and the compound is not approved by any major regulator for clinical use. Researchers should treat the molecule as an investigational tool, not a therapy.
Mechanism of Action
BPC-157 appears to act through several non-exclusive mechanisms. The most replicated involves upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) on endothelial cells, which promotes angiogenic sprouting at the site of injury and accelerates the formation of granulation tissue.
A second strand of evidence implicates the nitric-oxide (NO) system. BPC-157 modulates eNOS and iNOS activity in a context-dependent way, restoring NO tone in tissues where vascular function is compromised and dampening it where pathological inflammation dominates.
There is also growing interest in BPC-157's interaction with the gut-brain axis. Vagally mediated effects have been observed in models of inflammatory bowel disease and CNS injury, though the receptor target on neurons (if any) has not been definitively identified.
Research Summary
- Accelerated tendon and muscle healing with increased angiogenesis in rat tendon-injury models, measured by tensiometry and histology. [2]
- Protective effect against NSAID-induced gastrointestinal lesions in rats. [1]
- Pro-angiogenic activity associated with VEGFR2 receptor activation and up-regulation. [3]
- Accelerated recovery in rat models of muscle crush injury. [4]
- A 2022 review summarises reported central-nervous-system effects, including modulation of monoaminergic signalling. [5]
What we don't know yet
- No published human pharmacokinetic data for the most commonly studied administration routes.
- Long-term safety profile beyond 30-day rodent windows is essentially uncharacterised.
- The bioactive conformation in plasma is debated; the molecule's high reported activity despite a short half-life is not fully explained.
Protocol Considerations
Research framing only. The Protides Research Library does not provide dosing guidance for human use. The figures below summarise published research-protocol ranges and storage conditions; they are not clinical recommendations.
Stack Interactions
Storage & Handling
- Lyophilised
- −20 °C, desiccated and dark. Stable for at least 24 months.
- Reconstituted
- 2–8 °C, single-use aliquots preferred. Use within 14 days.
- Shelf life
- Lyophilised ≥ 24 months at −20 °C. Reconstituted ~14 d at 2–8 °C.
FAQ
Is BPC-157 a naturally occurring peptide?
The 15-mer fragment was rationally designed from a sequence in gastric juice protein; the intact parent has not been confirmed to exist endogenously.
What is the most robust preclinical finding?
Accelerated tendon and ligament repair in rodent transection models, replicated across multiple independent labs.
Does BPC-157 cross the blood-brain barrier?
Some functional CNS effects have been reported, but direct evidence of intact passage remains thin.
Why is the half-life so short?
It is rapidly hydrolysed by serum peptidases. The discrepancy between half-life and observed activity is an open mechanistic question.
Are there any approved therapeutic uses?
No. As of writing, no major regulator has approved BPC-157 for any clinical indication.
What purity benchmark should a research-grade vial meet?
≥ 98% by HPLC area-percent at 220 nm is typical for credible suppliers; many premium batches report ≥ 99%.
References
- [1]
- [2]Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healingJ. Physiol. Pharmacol., 2009
- [3]
- [4]
- [5]Pentadecapeptide BPC 157 and the central nervous systemNeural Regen. Res., 2022
